Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience

Overview of attention for article published in Frontiers in Pediatrics, August 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 2,016 followers.

RT @BernardorJulie: Our new multicentric study reported the use of cinacalcet in pediatric primary hyperparathyroidism in France. This trea…

14 Sep 2022

Reply Repost Favourite

Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience. The starting daily dose was 0.7 (0.6–1.0) mg/kg, with a maximum dose of 1.0 (0.9–1.4) mg/kg per day with follow-up for 2.2 (1.3–4.3) years. https://t.co

14 Sep 2022

Reply Repost Favourite

RT @BernardorJulie: Our new multicentric study reported the use of cinacalcet in pediatric primary hyperparathyroidism in France. This trea…

14 Sep 2022

Reply Repost Favourite

Our new multicentric study reported the use of cinacalcet in pediatric primary hyperparathyroidism in France. This treatment permits to correct hypercalcemia and decrease PTH levels. thank you ⁦⁦@FiliereOSCAR⁩ for the support https://t.co/dmhWCMAGRS

13 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.